Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with the Financial Conduct Authority's (the “FCA”) Disclosure and Transparency Rule 5.6.1R, notifies the market of the following:
At close of business on March 31, 2014, the Company’s issued ordinary share capital comprised 588,893,971 ordinary shares of 5 pence each with voting rights and a further 9,019,832 ordinary shares held in treasury.
Therefore the total number of voting rights in the Company is 588,893,971. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Deputy Company Secretary
For further information please contact:
+1 781 482 0733
+1 781 482 0999
+44 1256 894157
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
Click here for the PDF version of this press release.